Kliniken und Institute

Zentrum Pharmakologie und Toxikologie

Institut für Pharmakologie

• Tiburcy M, Didié M, Boy O, Christalla P, Döker S, Naito H, Karikkineth BC, El-Armouche A, Grimm M, Nose M, Eschenhagen T, Zieseniss A, Katschinksi D, Hamdani N, Linke WA, Yin X, Mayr M, Zimmermann WH (2011)
  Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. CIRC RES, 109: 1105-14.
• El-Armouche A, Wittköpper K, Fuller W, Howie J, Shattock MJ, Pavlovic D (2011)
  Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase. FASEB J, 25: 4467-75.
• Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, Schwoerer AP, Lau D, Fu X, Klingel K, Sydow K, Didié M, Seniuk A, von Leitner EC, Szoecs K, Schrickel JW, Treede H, Wenzel U, Lewalter T, Nickenig G, Zimmermann WH, Meinertz T, Böger RH, Reichenspurner H, Freeman BA, Eschenhagen T, Ehmke H, Hazen SL, Willems S, Baldus S (2010)
  Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. NAT MED, 16: 470-4.
• Wittköpper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A (2010)
  Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J CLIN INVEST, 120: 617-26.
• Wuertz CM, Lorincz A, Vettel C, Thomas MA, Wieland T, Lutz S (2010)
  p63RhoGEF--a key mediator of angiotensin II-dependent signaling and processes in vascular smooth muscle cells. FASEB J, 24: 4865-76.